Previous studies suggest that the EP300-ZNF384 fusion subgroup has a better prognosis compared to other pre-ALL subtypes, consistent with findings from a Japanese cohort [11, 12]. The gene discussed is ZNF384; the disease is acute lymphoblastic leukemia.